How much do you really know about metastatic urothelial carcinoma (mUC)? Take The Ultimate mUC Challenge, curated by our esteemed faculty, Prof. Dr. Axel S. Merseburger and Professor Tom Powles, to find out! 🔎 Test your knowledge of the current management of mUC as you progress through a series of challenging multiple choice questions and collect antibody tokens with each correct guess. 🔎 Not sure which answer to choose? No problem! You have different lifelines at your disposal to help you throughout the game. 🔎 The goal is to accumulate the maximum number of antibodies possible. Do you have what it takes? Make the right choices and become a master of managing mUC. Try it now! at https://lnkd.in/edg3TJFC --- This programme is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany and Astellas. #mUC #urothelialcarcinoma #oncology #medicaleducation #continuingmedicaleducation #cne #independentmedicaleducation #ime #SpringerIME
Springer Healthcare Independent Medical Education (IME)’s Post
More Relevant Posts
-
Professor with tenure; GI oncologist & Neuro-Oncologist; Lab-based Physician-Scientist and Clinical Investigator
Even with the Memorial Day holiday coming up, I'm already looking ahead to end of next week and the start of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. It's always a busy and productive time, and this year's meeting includes a diverse set of presentations that I am excited to be a part of. In addition to being an invited panelist for the Caris Life Sciences Fellows Forum focused on career paths for early-career investigators and trainees, I will be a speaker at the Education Session taking place Saturday, June 1 from 1:15-2:30 pm, focused on Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates. The title of my talk will be: Dynamic Evaluation of Biomarkers in Patients Treated With Antibody-Drug Conjugates (ADCs). Looking forward to this session, as it focuses on an fast-growing form of developmental therapeutic class of cancer drugs. Join us in Hall D1 if you'll be at #ASCO24! with Chair and Speaker Dr. Giuseppe Curigliano, speaker Dr. Patricia LoRusso, Education Chair Dr. Thomas LeBlanc https://lnkd.in/gmADupWu #oncology #oncologist #cancer #cancertreatment #developmentaltherapeutics #tumorbiology #molecularlytargetedagents #cancerbiology #cancerbio #cancertherapy #cancertherapeutics #medicine #physicianscientist #mdphd #medicine #medical #ASCO #science #cancerscience #laboratory #lablife #medicalife
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
-
Associate Professor, Dept Microbiology & Immunology-Doherty Institute, Lab Head Brain Cancer Biology, Lecturer, The University of Melbourne, Former Marie-Curie Fellow, DKFZ Connect
Congratulations Marija Dinevska! awarded the ECR paper of the year - by Matrix Biology Society of Australia and New Zealand (MBSANZ) The study used Opal Polaris 7 Color multiplex-IHC from Akoya Biosciences, Inc. for cell spatial analysis. Key discoveries: 1/ immune cells, including cytotoxic T-cells, are sequestered in ECM-rich regions in brain tumors, most prominently in ECM-rich perivascular regions. 2/ Metastatic Brain Tumor ECM differs, compared with ECM in #glioblastoma #GBM. With this in mind, we are investigating ways to enhance anti-tumor immunity by mobilizing the 'ECM-trapped' immune cells. Samuel Widodo University of Melbourne The Peter Doherty Institute for Infection and Immunity #ecm #oncoimmunity #braincancer #spatialbiology
Congratulations to Marija Dinevska & colleagues, for being awarded the MBSANZ 2023 ‘Paper of the Year’ in the Early Career Researchers Category. You can read the paper here: https://lnkd.in/gJYCPFqf
Spatial analysis of the metastatic brain tumor immune and extracellular matrix microenvironment
sciencedirect.com
-
On a mission to make cancer a nonfatal disease with the help of AI | Adherent of AI-driven personalized medicine | EVP of Science and Technology @ Zephyr AI | Limited Partner @ AAL VC
The countdown is on. Next week, I'm heading to Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24). It's one of the most significant events in the oncology world, bringing together a global community of researchers, clinicians, advocates, and patients in the fight against cancer. For me, #ASCO24 is more than just a conference; it's a chance to: - Dive into the Latest Research: Thousands of abstracts will be presented, showcasing cutting-edge advancements across all aspects of cancer care. I'm eager to learn about new therapies, diagnostic approaches, and breakthroughs that can transform patients' lives. Discussing the evolving landscape of cancer treatment is crucial for staying updated on the latest developments and best practices in patient care. - Connect with Experts: Meeting and exchanging ideas with leading oncologists, scientists, and industry innovators is an invaluable experience. It fosters collaboration and fuels inspiration for advancing cancer care. - Share Our Recent Developments: Zephyr AI team will present a poster and share our findings on the "Evaluation of a Novel Machine Learning Method for PARP Inhibitor Sensitivity Prediction Using Real-World Data." Abstract # 5583 / Poster Bd # 454, presented by Emily Vucic et al., June 3rd, 9 am—12 pm: https://lnkd.in/g8wKqB8v In the meantime, what are you most interested in learning about from #ASCO24? Share your thoughts and questions. See you in Chicago!
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
-
✨ Yesterday I was watching a super informative lecture from the American Society of Clinical Oncology (ASCO) Annual Meeting on #precisiononcology in #pediatric and #AYA #sarcomas by Dr. Jack Shern. Here are some key takeaways: 🔬 Dr. Shern highlighted the critical aspects of precision oncology, emphasizing its potential to provide accurate diagnoses, develop targeted therapies, and ultimately improve patient outcomes. This approach is particularly crucial for rare pediatric sarcomas, where personalized treatment strategies can make a significant difference. 🧬 Major international efforts involving comprehensive molecular profiling that aim to identify actionable alterations. #MAPPYACTS (Europe) #INFORM (Germany) #ZERO childhood cancer (Australia) National Cancer Institute (NCI) Pediatric #MATCH (USA) #KiCS (Canada) 📊 Key Findings: 🔹 37% of enrolled cases across these studies had a #sarcoma diagnosis. 🔹 33% of sarcoma cases had #actionable alterations, although the definition of "actionable" varied across studies. 🔹 #Germline alterations were identified in 10-20% of #pediatric and #AYA sarcoma cases. Challenges: 🔺 Limited Actionable Alterations. 🔺Implementation Barriers: High costs, accessibility, and inconsistent initiation of molecular testing. 🔺Underutilized Germline Testing: it often goes untested and uncounseled. etc 🔗 Key recommendations: 🔹Routine Molecular Profiling: Implementing comprehensive molecular profiling to ensure accurate diagnoses and prognostic assessments. 🔹Targeted Drug Strategies: Developing and refining targeted drug strategies and combination therapies specifically for sarcoma patients. 🔹Enhanced Patient and Family Engagement: Fostering transparent communication and shared decision-making processes with patients and their families. #ASCO2024 #pediatriconcology #precisionmedicine #childhoodcancer #sarcomaresearch #liquidbiopsy #genomicprofiling
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
-
Some interesting, counter-intuitive insights here on PBSA from Daniel Whiteman
Leumi UK’s Relationship Director, Daniel Whiteman, reveals key insights into the booming Purpose-Built Student Accommodation (PBSA) sector. The PBSA sector is experiencing unprecedented growth, with a staggering 69% increase in investment in 2022. However, not all investments are created equal. The key lies in understanding the unique dynamics of each university location. However, success in this sector requires a case-by-case approach. Expert advice is crucial, not only in understanding local dynamics but also in designing developments that cater to students' preferences. With the right insights and strategic planning, the future of the PBSA sector is undeniably bright. Read full article here on EG: https://lnkd.in/ekAT_AaG Mickey Schiller | Peter Clayton | Andy Mallin #PBSA #InvestmentInsights #LeumiUK
Dig into the detail for PBSA’s best returns | EG News
egi.co.uk
-
CMO Oncology Consulting | Clinical Development | Strategy |Medical Affairs | IND | NDA | CDP | Protocol design | Phase 1 | FIH | Phase 3 | Go/NoGo | GNG | | acquisitions | data review | teaching | mentoring
mTPI study design for oncology phase 1 studies: a practical approach for the Medical Director and Clinical Scientist. Enjoy 28 minutes of teaching, and tell us what you want to see next. https://lnkd.in/gBmMxcpD
mTPI a practical approach
https://www.youtube.com/
-
Leumi UK’s Relationship Director, Daniel Whiteman, reveals key insights into the booming Purpose-Built Student Accommodation (PBSA) sector. The PBSA sector is experiencing unprecedented growth, with a staggering 69% increase in investment in 2022. However, not all investments are created equal. The key lies in understanding the unique dynamics of each university location. However, success in this sector requires a case-by-case approach. Expert advice is crucial, not only in understanding local dynamics but also in designing developments that cater to students' preferences. With the right insights and strategic planning, the future of the PBSA sector is undeniably bright. Read full article here on EG: https://lnkd.in/ekAT_AaG Mickey Schiller | Peter Clayton | Andy Mallin #PBSA #InvestmentInsights #LeumiUK
Dig into the detail for PBSA’s best returns | EG News
egi.co.uk
-
In these uncertain times, one thing remains constant: cancer hasn't stopped, and neither will we. 💪 Supporting women-led cancer research is close to my heart, and with your help, we can sustain and advance this vital work. Please consider donating today to help fuel the future of cancer research. Every contribution makes a difference. https://bit.ly/4cg4laX #CancerResearch #SupportWomenInScience #DonateToday
ACS ResearcHERS May 1 Launch
https://www.youtube.com/
-
Catch the replay of MedNews Week Week's recent keynote with Dr. Brian Van Tine from Washington University in St. Louis, MO, Department of Medicine, discussing the translation of metabolic therapies into sarcoma! 🔗 EVENT LINK: https://lnkd.in/g2zC5uR2 🏆 Notable Achievements: 👨🔬 Head of Developmental Therapeutics (Phase 1) Sarcoma Program, Alvin J 🏆 Globally recognized for leadership in Sarcoma Research and Treatment 🏆 Honored with various awards, including presenting the 2014 Rosenfeld Lecture for the Sarcoma Alliance for Research and Collaboration 🏆 Secured First Place for the poster "Loss of Taspase1 Abrogates HER2/neu Induced Breast Cancer" at the Breast Cancer Symposium, Washington University 🏆 Completed the Physician Scientist Training Program at Washington University 🎓 A dedicated mentor, guiding over 12 mentees at all stages of training. Yan Leyfman, MD Maduri Balasubramanian Sean Jackewicz Soumiya Nadar Rabab Hunaid Abbas Emad Bin Zahid Ahmed Hashim Azeez Vallabhaneni Sree Harshitha Muskan Joshi Alexandra Van de Kieft Harshal C. Gayathri Pramil Menon Jade Gambill Fabiha Amin #SarcomaAwareness #SarcomaSupport #BoneCancer #SoftTissueSarcoma #CancerAwareness #FightSarcoma #CureSarcoma #SarcomaWarrior #SarcomaResearch #RareCancer #SarcomaCommunity #SarcomaSurvivor #SarcomaStrong #EndSarcoma #CancerResearch #SarcomaWarrior #ChildhoodCancer #SarcomaFighter #SarcomaSupportGroup #TogetherAgainstSarcoma #MetabolicTherapy #MetabolicHealth #NutritionalTherapy #KetogenicDiet #IntermittentFasting #MetabolicSyndrome #Biohacking #MitochondrialHealth #MetabolicFlexibility #FastingForHealth #LowCarbLiving #HighFatDiet #MetabolismBoost #NutritionalScience #TherapeuticFasting #NutritionalMetabolism #EnergyMetabolism #NutritionAndHealth #CellularHealth #MetabolicBalance
MedNews Week Keynote Lecture: Dr. Brian Van Tine
https://www.youtube.com/
-
While a direct comparison between the HARMONi-A and the ORIENT-31 study may not be appropriate, the PFS data from both studies are remarkably similar despite Akeso highlighting the unique mechanism of action of ivonescimab. ✅ HARMONi-A mPFS: 7.06 months vs 4.80 months (HR: 0.46, P < 0.0001) ✅ ORIENT-31 mPFS: 6.9 months vs 4.3 months (HR: 0.46, P < 0.0001) ORIENT-31: https://lnkd.in/gQxtMV6w
#ASCO24 #LungCancer I missed an important abstract. Was the market concerned about the side effects of the HARMONi-A study? The HARMONi-A study investigated EGFR+ NSCLC patients who progressed after third-generation EGFR-TKI treatment and included those who had not been exposed to systemic chemotherapy except for EGFR-TKIs. Although the 7-month mPFS showed some improvement compared to the five months typically seen in similar treatment lines, grade 3 or higher TEAEs were higher in the ivonescimab group (61.5% vs. 49.1%). During the four cycles of the induction period, patients received ivonescimab, pemetrexed, and carboplatin. As seen in the FLAURA2 study, this period is associated with many side effects. The frequency of these side effects significantly decreases after carboplatin is discontinued. However, considering the characteristics of second or third-line patients, the initial aggressive combination therapy might worsen their condition. The FLAURA2 study confirmed the efficacy of combining third-generation EGFR-TKIs with chemotherapy. This evidence allows us to consider combinations of EGFR-TKIs and ADCs, which several groups are already exploring. While we need to review the detailed data from HARMONi-A, these findings could provide BioNTech SE with intriguing insights. Abstract: 8508
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
More from this author
-
Successful IME programs using adult learning principles: Part 7 (Diversity, Equity, Inclusion, and Accessibility)
-
Successful IME programs using adult learning principles: Part 6 (Need to know – what’s in it for me?)
-
Successful IME programs using adult learning principles: Part 5 (Experience-based learning)